Sentences with phrase «growth stock purchases»

My May saw two dividend growth stock purchases — both of which were new positions in the portfolio.

My Undervalued Dividend Growth Stock Purchase -LSB-...]

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

BAML also cites corporate earnings growth as a tailwind to stock prices, though it notes that global purchasing manager data is «rolling over,» signaling a slowdown to come.

Because PE is a measure of earnings over time, you can think of it as representing the number of years required to pay back a stock's purchase price (ignoring inflation, earnings growth and the time value of money).

Since the growth is not measured on a per share basis, Rosenstein claims management can drive up its payout by acquiring new production volume, even if it means diluting the value of its shares to purchase Rice's wells with stock, which Rosenstein believes is undervalued.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Second, if — as many people believe — the publication of findings on the value premium has led to cash flows that have caused it to disappear, we should have seen massive outperformance in value stocks as investors purchased those equities and sold growth stocks.

The Compensation Committee believes that options to purchase shares of our common stock, with an exercise price equal to the market price of our common stock on the date of grant, are inherently performance - based and are a very effective tool to motivate our executives to build stockholder value and reinforce our position as a growth company.

The Basics for Investing in Stocks Different flavors of stocks The importance of diversification How to pick and purchase stocks Key measures of value and finding growth When to sell What's your rStocks Different flavors of stocks The importance of diversification How to pick and purchase stocks Key measures of value and finding growth When to sell What's your rstocks The importance of diversification How to pick and purchase stocks Key measures of value and finding growth When to sell What's your rstocks Key measures of value and finding growth When to sell What's your return?

If the whole thing — the rises in stock prices, in corporate earnings, in the housing market, even in job growth — is driven solely by the flood of money, or whether five years of zero - interest rates and trillions of dollars in bond purchases have succeeded at getting a more resilient economic engine for the United States up and running.

«Dividend Growth Investing is about purchasing dividend - paying stocks that grow their dividends over time, and then holding onto those investments for quite a while as you receive continually increasing passive income from those companies..»

Periodically, I will write about dividend stocks that we purchase or own, as an example of how the dividend growth investing (DGI) strategy works, the risks that you have to deal with in pursuing the strategy and the long - term patience that DGI requires.

The self - reversing nature of the Fed's repos and reverse repos, many of which are «overnight» rather than «term» agreements (that is, ones providing for repurchase a day after the original purchase) has caused the Fed to prefer them as a means for achieving temporary adjustments to the money stock, while treating outright security purchases as a way of providing for permanent monetary expansion, and especially for secular growth in the demand for Federal Reserve notes.

Different flavors of stocks The importance of diversification How to pick and purchase stocks Key measures of value and finding growth When to sell What's your return?

However I am using this opportunity to purchase more dividend growth stocks.

Last week, we purchased Solid Stock Art to continue the growth of our library.»

This fund will perform well as long as the long term economic growth and prosperity in China continues, coupled with rising speculative stock purchases in -LSB-...]

There i need maybe faster growth (but more dangerous) and probably will need to sell stocks to purchase a house.

Different flavors of stocks The importance of diversification How to pick and purchase stocks Key measures of value and finding growth When to sell What's your return?

No.Yrs = Consecutive years of higher dividends; MR = Most Recent; DGR = Dividend Growth Rate; * Offers Company - sponsored Dividend Reinvestment / Stock Purchase Plan.

When the economy is expanding, earnings tend to grow across the market and in such an environment, investors historically could purchase value cyclical stocks at a much more attractive price than evergreen growth stocks.

When I purchase a dividend growth stock, I typically like to give a detailed summary of a company's financial strength.

If you are a value investor, it does not make sense to spend time looking at stocks with uber - growth if they can not be purchased at attractive prices.

The stock and bond funds can provide long - term growth to help maintain your purchasing power over the course of a long retirement and also act as a source of liquidity for any additional spending money you need.

Our superb investment results in General Growth Properties, where the stock price had declined more than 99 % before we made our first purchase, gave us confidence that we could assist Valeant in a turnaround after its stock price collapse.

The Firm believes diversified portfolios of the stocks of companies meeting its quality - growth criteria, purchased at reasonable prices, offer superior risk - adjusted returns over the long term.

However I am using this opportunity to purchase more dividend growth stocks.

So if you do decide an annuity is for you, be sure that you have enough savings left over in a diversified portfolio of stocks and bonds to generate some growth to protect your purchasing power from inflation and to provide a stash to meet emergencies and fund the occasional indulgence.

(You can read about that purchase in «A Top Dividend Growth Stock for 2014.»)

In my recent post, «Stock Purchase: T Rowe Price (TROW),» I mentioned that I had developed a dividend growth stock ranking system to help speed up my stock selection proStock Purchase: T Rowe Price (TROW),» I mentioned that I had developed a dividend growth stock ranking system to help speed up my stock selection prostock ranking system to help speed up my stock selection prostock selection process.

Note, the REIT purchases are technically not dividend growth stocks (yet?!)

It should not be used as an end all be all for purchasing a dividend growth stock.

If you purchase a stock that offers that type of dividend growth trajectory, you will be earning an 8 % annual yield in no time.

Every stock was, at the time of purchase, in my Top 40 Dividend Growth Stocks eBook.

The additional shares purchased with reinvested dividends have grown the portfolio enough so that its overall income rises faster than the dividend growth rate of any stock in it.

Negative interest rate policy (NIRP) is not bolstering economic growth; asset purchases by foreign central banks have merely provided an additional avenue for foreign money to find its way into positive yielding U.S. debt and the perceived safety of U.S. stocks.

He's hoping this strategy will bring him more success with his latest purchase: Canopy Growth Corp. a Canadian marijuana stock.

Indeed, the rest of the world's central banks are purchasing assets (e.g., government debt, investment grade corporate bonds, higher - yielding junk corporates, stocks, etc.) with QE «funny money» in the hopes that it will boost economic growth.

I sold the stocks that I had accumulated through my previous employee purchase plan and sold all of my holdings in the Bank of Nova Scotia since it has been flat - lining for the past quarter and did not show many signs of future growth.

The early 1970s was the era of the «Nifty Fifty,» in which the prevalent investing philosophy was that the only stocks that should ever be purchased — and purchased regardless of their current prices — were the 50 biggest growth stocks in the world.

The dividend growth is quite low, so I would use this stock as a money making machine to generate cash which can be later used to purchase more shares of another dividend growth stock.

Investors who purchase growth stocks receive returns from future capital appreciation (the difference between the amount paid for a stock and its current value), rather than dividends.

Upon purchasing a stock, an investor becomes a shareholder in that particular company, and is able to benefit from its earnings growth and dividend payouts, while having voting rights.

And, I am looking to deploy this money to purchase more cash generating machines (dividend growth stocks) in the coming days.

First off, I would like to say thank you for being such an inspiration to beginner dividend growth investors like myself Secondly, congratulations on the book and the purchase of another high quality dividend paying stock!

Which is why even if you decide an immediate annuity is right for you, you want to be sure you have plenty of other savings invested in stocks, bonds and cash equivalents that can provide capital growth to maintain purchasing power and provide extra cash should you need it for emergencies and such.

As an equity position, investors who purchase stock in a company seek to benefit from its continued growth and ability to generate profits, just as other owners of the company would receive.

If only there was a way to get the best of both worlds today... to purchase both a high - quality dividend growth stock today AND collect a double - digit annual income stream from those very same shares over the next 12 months.

The flip side — finding undervalued stocks — occurs when the PEG ratio is low and the investor is able to purchase growth at a reasonable price.